Oberweis Asset Management Inc. Acquires 169,600 Shares of MannKind Co. (NASDAQ:MNKD)

Oberweis Asset Management Inc. increased its holdings in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 21.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 968,400 shares of the biopharmaceutical company's stock after acquiring an additional 169,600 shares during the period. Oberweis Asset Management Inc. owned about 0.35% of MannKind worth $6,227,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MNKD. Price T Rowe Associates Inc. MD grew its holdings in shares of MannKind by 12.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 175,009 shares of the biopharmaceutical company's stock worth $1,126,000 after purchasing an additional 18,806 shares during the last quarter. Dark Forest Capital Management LP lifted its position in MannKind by 71.1% during the 4th quarter. Dark Forest Capital Management LP now owns 34,975 shares of the biopharmaceutical company's stock worth $225,000 after buying an additional 14,528 shares in the last quarter. Hsbc Holdings PLC grew its holdings in MannKind by 49.7% during the 4th quarter. Hsbc Holdings PLC now owns 31,327 shares of the biopharmaceutical company's stock worth $203,000 after acquiring an additional 10,407 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in MannKind by 441.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 30,693 shares of the biopharmaceutical company's stock worth $197,000 after acquiring an additional 25,025 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in MannKind by 3.3% in the 4th quarter. MetLife Investment Management LLC now owns 158,481 shares of the biopharmaceutical company's stock valued at $1,019,000 after acquiring an additional 5,110 shares in the last quarter. 49.55% of the stock is owned by institutional investors and hedge funds.

MannKind Trading Down 0.2 %

Shares of NASDAQ:MNKD traded down $0.01 during midday trading on Monday, hitting $4.73. The company had a trading volume of 1,334,220 shares, compared to its average volume of 2,392,022. The firm has a fifty day simple moving average of $5.01 and a 200 day simple moving average of $5.94. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 67.57 and a beta of 1.22. MannKind Co. has a 12 month low of $4.11 and a 12 month high of $7.63.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The company had revenue of $76.78 million during the quarter, compared to analyst estimates of $74.99 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. Equities analysts forecast that MannKind Co. will post 0.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MNKD has been the topic of several research analyst reports. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of MannKind in a research note on Thursday, February 27th. StockNews.com raised MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th. Finally, Mizuho assumed coverage on MannKind in a research note on Thursday, April 10th. They set an "outperform" rating and a $12.00 price target on the stock. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $9.56.

MannKind Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.